MedTrace Logo

Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients

NCT04151680 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-09-09

No results posted yet for this study

Summary

Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.

Uncertainty about the potential implications of a strategy of intermittent anticoagulation after percutaneous coronary intervention exists.

The investigators will perform a case-control study to evaluate the safety and efficacy of anticoagulation on demand in high bleeding risk (HBR) patients with paroxysmal atrial fibrillation after percutaneous coronary intervention.

Conditions

Interventions

DRUG

Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban

Patients will receive chronic treatment with a novel oral anticoagulant drug

DRUG

Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban

Patients will receive intermittent treatment with a novel oral anticoagulant drug

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Carlo Gaudio, MD · University Sapienza

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-11-30
Completion
2023-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04151680 on ClinicalTrials.gov